Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr.DeGrado and Jun Wang go way back. I'm sure the original study findings were known well before August.
Understand the science, understand why the finding of a second antiviral MOA is positive news. Sleep peacefully.
GLTA(Longs)
Some might find this interesting. In August Jun Wang of the University of Arizona published the following article.
Targeting Viral Proteins and Host Factors for Discovery and Development of Antivirals Against Influenza, Enterovirus, and Coronavirus (full text: https://repository.arizona.edu/handle/10150/661245?show=full)
In August I notified Innovation Pharmaceuticals of the publication and the findings regarding heparan. Fascinating, now, to see this follow-up(?) paper co-authored by Jun Wang, DeGrado and others. Can't wait to see what comes of this research.
Edit: I wouldn't be surprised to see this article appear on the Innovation Pharmaceuticals Updates page.
Fkn bone heads indeed. Well said.
Agreed. It is the body of evidence that has been amassed by Innovation Pharmaceuticals that is generating excitement.
Taking B into phase II along multiple therapeutic paths (OM, IBD, antibiotic, antiviral) was primarily designed to secure the bona fides of B and strengthen negotiating position for the platform without incurring the massive cost of a phase III trial.
The secondary benefit of the platform strategy has been the slow build up of confidence among investors. Longs have held and accumulated. Others have marked their calendar and timed their entry. Few, if any, will cut and run before TL results. Buying will dominate the chart until phase II results are known.
After? I've always held that a deal would define the baseline share price and not market makers or market sentiment.
Multiple BP bidding on the potential revenues of the Brilacidin platform will set the new baseline share value. Market sentiment will shape dips and peaks afterward.
EDIT: Lock Confirmed. http://www.ipharminc.com/press-release/2021/11/3/database-lock-completed-for-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19
A trigger for increased investor entry. Volume will continue to increase.
leak= 12 million volume
3.3 mil Tuesday= mounting evidence and B's track record
That said; We could see double digit volume by Friday. (That is, of course, if Innovation Pharma doesn't drop news early for shock value.)
As of Kip Bay Select SEC filing in May they had 21,200,000 shares of IPIX Common Stock Class A
https://sec.report/Document/0001213900-21-024168/
How does that reflects current holdings? I can't find a more recent filing.
Two different Kips Bays.
Aspire has entered into a funding agreement with Kips Bay Medical.
http://www.kipsbaymedical.com/
Kips Bay Select LP is an investor in Innovation Pharmaceuticals.
https://sec.report/CIK/0001845716
Apart from the coincidental similarity in name I do not believe there is a corporate connection.
Its a bit of a gray area. From Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture Increasing evidence shows that both natural and synthetic antimicrobial peptides (AMPs), also referred to as Host Defense Proteins/Peptides (HDPs), can inhibit SARS-CoV-2, paving the way for the potential clinical use of these molecules as therapeutic options. In this manuscript, we describe the potent antiviral activity exerted by brilacidin—a de novo designed synthetic small molecule that captures the biological properties of HDPs—on SARS-CoV-2 in a human lung cell line (Calu-3) and a monkey cell line (Vero). (https://www.mdpi.com/1999-4915/13/2/271)
While Brilacidin is often described as a non-peptidic it is a synthetic modelled after HDP and intended to offer all the advantages of a HDP while reducing many of the risks and manufacturing challenges of natural HDPs. Therefore, much of the scientific literature describing the potential value of HDPs (peptides) as therapeutics are relative to a discussion/evaluation of Brilacidin's potential.
There is a growing body of research regarding AMPs and HDPs as therapeutics. Understanding the wide range of antiviral, antibacterial and immunomodulatory characteristics of these versatile antimicrobial peptides is crucial to understanding Brilacidin's potential (and value).
Get this in circulation.
Brilacidin currently being used in Florida hospitals to treat patients. Plural patients. Validated by a matter-of-fact quote. As if to say...For treatment of COVID-19...Brilacidin!
https://www.palmbeachpost.com/story/news/coronavirus/2021/10/13/covid-patients-request-ivermectin-denied-hospital-lawyer-claims/8437265002/
Thanks Snowy. I'd also add (in support of your post), that discussions here are often short on citation and perspective. So for those who might be reading and wish to go deeper than the headline or inflammatory quote here's a link to an article about the firings that offers greater contest.
Excerpt: The hospital network added it "regrets losing any employee under such circumstances, but as health care professionals and members of the largest health care provider in the state, we understand our unique responsibility to protect the health of our patients and each other."
Full article: https://www.lohud.com/story/news/coronavirus/2021/10/05/northwell-fires-1-400-workers-due-vaccine-mandate-but-76-k-got-shots/6002297001/
The page has been down since, at least, Sunday evening. The company has been notified.
It takes nine months to have a baby. You can’t hire nine women, at any price, to complete the job in one month.
Some processes simply take time.
Results will be available soon.
A new entity with apparent wisdom and support for the success of Innovation Pharmaceuticals who manages to introduce gems of doubt in every post. Hmmm.
Per Innovation Pharmaceuticals; "... we are now quickly approaching the last of the 60th day post treatment telephone follow-up visits with trial participants, which are scheduled to take place by the first week of August." (https://www.ipharminc.com/new-blog/2021/7/16/shareholder-alert-covid-19-trial-update-upcoming-antiviral-conferences-july-16-2021)
Final data point has not been captured. Anticipate an update in the first week of August.
For those who like meat with their bones:
https://clinicaltrials.gov/ct2/show/NCT04960202
A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19
The drug targets a different patient population than does Brilacidin.
It is not a PR. Innovation Pharmaceuticals has delivered a Shareholder Alert on the Update page of their website.
http://www.ipharminc.com/new-blog/2021/7/16/shareholder-alert-covid-19-trial-update-upcoming-antiviral-conferences-july-16-2021
The devil is in the details.
I hope you (and true Longs), get all you wish for on your Birthday!
True, the increase to total deaths was a blip. ( With empathy and compassion felt for the victims. I have lost.) There are a million ways to die and SARS-COV-2 has formidable competitors in that sweepstake.
Consider the economic impact. Empty office buildings. Empty plains. Empty trains, buses and commuter lanes. Empty municipal tax coffers. Empty pockets.
Effective treatments, vaccinations, social adaptations were essential to limit the economic impact. And in many respects fear of the economic peril is what will motivate business and government to seek cure and prevention of the next pandemic.
Drug pricing is, in part, based on preserving quality of life of a patient. Quality of life has a it’s proxy in economics. On a macro scale the value of a cure, Brilacidin we hope, is, in part, derived from the power to prevent economic disaster.
There are few empty houses. Not related but, there is in fact a housing shortage so it’s a poor example of COVID’s impact. But in my lifetime there have been few if any (OPEC oil crisis?) economic and socially disruptive events comparable to the COVID pandemic. A hefty value will be assigned to a cure. Brilacidin, if efficacy is demonstrated, will make billionaires out of some and millionaires out of many Longs.
“A large investor…”
Invest in a review of trial details.
Clinicaltrials.gov
I don’t recall trial outcomes being represented this way by Innovation Pharmaceuticals. Please substantiate your position by citing company-published results.
As for sachets: phase II, as a cost savings effort, was conducted using a Brilacidin in water solution. (Swish and spit.) Final formulation and distribution in patient-prepared, dose controlled sachets was offered as a potential next step methodology which might easily support expanded distribution. (Expanded for phase III while reducing potential of mis-measured dosing and a dry run (no pun intended) for eventual commercial distribution.
If you have information that disputes this post please provide links. Innovation Pharmaceuticals has NEVER reported diminished efficacy correlated to Brilacidin shelf life.
The ASV2021 presentation; “Brilacidin, a Host Defense Protein/Peptide Mimetic, Shows Potential as Broad Spectrum Inhibitor of Acutely Infectious Viruses” is very likely embargoed. Presentation embargo is standard practice employed by conference organizers (and journal publishers). It will not be available to the public until after it has been presented at ASV2021. Innovation Pharmaceuticals, no doubt, wishes to publish the update but will not do so until after the presentation.
clinicaltrials.gov
Informed investors strengthen a company’s foundation. Know what (and why), you own.
Thank you, much appreciated.
Are you suggesting SARS-COV-2 is a retro virus that goes dormant in the infected host only to reactivate at a later date? If so, do you have any documentation, articles or scientific papers, that suggest this is so and might provide additional information for investors?
Whose leaving it out? It’s in the headline. It’s in the article. Purchase contingent of efficacy. Similar to what all investors must keep in mind for Innovation Pharmaceuticals and Brilacidin.
GLTA(Longs)
The US and other governments are still in the market for therapeutics. Defeating COVID-19 and preparedness for, possible, future events will require a multi-front battle plan. Based on this report the willingness and wisdom to commit upfront dollars for therapeutics still exists.
If Brilacidin Phase II is successful there will be opportunities.
US to shell out $1.2B for supplies of Merck's potential Covid-19 antiviral
https://endpts.com/us-to-shell-out-1-2b-for-supplies-of-mercks-potential-covid-19-antiviral/
GLTA(Longs)
Background: Independent Data Monitoring Committees
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516383/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181557/
Two excellent papers on the Independent Data Monitoring Committee. I highly recommend that investors review to understand the purpose, make-up and relationship between IDMCs and those running clinical trials. IDMCs are independent from the FDA and in an ethically performed clinical trial are wholly independent of the trial sponsor.
Excerpt: An Independent Data Monitoring Committee (IDMC) duty is to ensure that the interests of the patients entered on the trial are being well-served (i.e., that the risk-benefit ratio is appropriate) and that the scientific integrity of the trial is maintained during the interim between trial initiation and trial completion. Industry sponsors form IDMCs to ensure an independent assessment to assure that the study participants are not exposed to unnecessary or unreasonable risks as a consequence of their trial participation, and to ensure that the study is being conducted according to highest scientific and ethical standards.
There are many pricing strategies (for pharmaceuticals) that can be applied, depending on the drug type, the company’s objectives, the competition and the market. Because of the specific distribution and selling structure of pharmaceutical products, four can be used to set drug prices: cost-based pricing, value-based pricing, competition-based pricing and price skimming.
https://www.pharmexec.com/view/price-right-overview-us-pricing-strategies
Excellent series of posts. Innovation Pharmaceuticals, with Brilacidin poised, is in an increasingly positive position. The results of Phase II could smash down previously locked doors to numerous opportunities and fill coffers.
GLTA(Longs)
Clinical Trials.gov is updates as soon as new data is presented by trial “owner”.
https://support.nlm.nih.gov/knowledgebase/article/KA-04924/en-us
How often are studies updated in ClinicalTrials.gov?
Views: 762
The National Library of Medicine updates studies in the ClinicalTrials.gov database when we get information from the organizations that are doing the trials. We add new studies and update ongoing studies as new information becomes available, such as a new site being added or a change in the study's recruitment status.
Although the National Library of Medicine maintains the database, the content is provided by the organizations that conduct the studies so the frequency of updates depends on them.
Thank you.
Do you have a link to the notification?
NP. I didn’t get it but hope the world does. :)
I give up, IOM? Where does the t fit?
Timed release Brilacidin Phase I- Ulcerative Colitis.
http://www.ipharminc.com/press-release/2020/2/13/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin
I took a moment to reread this morning's Blog Update. The update contained much that was unknown and/or unconfirmed. I found the information to be very useful and hopefully impactful for those thinking of investing in Innovation Pharmaceuticals.
GLTA(Longs)
From the Update:
With enrollment in the Company’s Phase 2 trial of Brilacidin for treatment of COVID-19 proceeding toward completion and release of topline results, testing of Brilacidin at independent labs against multiple viruses is ongoing. Brilacidin has now been evaluated in vitro in 10 separate human cell lines, showing consistent and potent inhibition against coronaviruses, alphaviruses and, most recently, bunyaviruses.
Brilacidin lab results against alphaviruses are to be provided, this July, in an Oral Presentation at the American Society of Virology’s 2021 annual conference. Brilacidin lab results in Human Coronaviruses (H-CoVs) (OC43, 229E, NL63) are being prepared for peer-review submission.